Amir Fathi, MD, Massachusetts General Hospital

Optimizing Treatment Selection for Patients with FLT3-ITD AML

July 24th 2023

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

July 17th 2023

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

July 17th 2023

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

July 12th 2023

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

June 26th 2023

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

June 26th 2023

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Progress in the Treatment of AML

July 20th 2020

Implications for Treating AML With CC-486

July 20th 2020

CC-486 Maintenance Therapy in AML

July 20th 2020

Gemtuzumab for AML

July 20th 2020

CPX-351 in Newly Diagnosed Secondary AML

July 20th 2020

Differentiation Syndrome and IDH Inhibitors in AML

July 20th 2020

IDH Inhibitors and MDS

July 20th 2020

IDH1/2 Inhibitors for AML

July 20th 2020

IDH Mutations in AML

July 20th 2020

FLT3 Triplet Regimens for AML

July 20th 2020

Monitoring Response to Venetoclax Regimens in AML

July 20th 2020

Venetoclax in AML: Safety Profile

July 20th 2020

Optimal Use of Venetoclax in AML

July 20th 2020

VIALE Studies in AML

July 20th 2020